Last reviewed · How we verify
Echinaforce tincture
Echinaforce tincture, marketed by A. Vogel AG, is a well-established product in the herbal supplement category. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the potential for increased competition post-patent expiry.
At a glance
| Generic name | Echinaforce tincture |
|---|---|
| Also known as | Echinaforce drops |
| Sponsor | A. Vogel AG |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Echinaforce COVID-19 Shedding Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |